Research Article

RP-HPLC Method Development and Validation for Quantification of Fexofenadine in Pharmaceutical Products

Number: 32 December 31, 2021
TR EN

RP-HPLC Method Development and Validation for Quantification of Fexofenadine in Pharmaceutical Products

Abstract

Fexofenadine belongs to the antihistamine family of drugs. It is used to treat seasonal allergic rhinitis symptoms. In this study, a rapid, simple and sensitive liquid chromatographic method for the quantitative determination of fexofenadine was optimized and validated. Agilent Extend C18 column was used to perform the separation. The optimum chromatographic separation was achieved by the mobile phase consist of acetonitrile and 20 mM KH2PO4 solution (pH 7.5) in 35:65 ratios respectively. The flow rate of 1.2 mL min-1 with a standard retention time of 3.5 min at a wavelength 220 nm was optimized. The developed method has been validated in terms of their linearity, specificity, precision, accuracy, limits of detection and quantification, and robustness as per I.C.H. guidelines. The developed method has shown excellent linearity, precision, and recovery. There were no spectral or chromatographic interferences from non-medicinal ingredients found. Within a concentration range of 10–60 g mL-1, the correlation coefficient was greater than 0.999. Low relative standard deviation values were obtained in the results of intra-day and inter-day precision tests. The method's accuracy ranged from 99.45 to 100.52 %. The present analytical method can be used to quantify fexofenadine in pharmaceutical preparations.

Keywords

References

  1. O’Neil MJ: The Merck index: an encyclopedia of chemicals, drugs, and biological. 13 edition. Merck & Co., Inc., Whitehouse Station, NJ; 2001.
  2. Simpson K, Jarvis B: Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000, 59:301-321.
  3. Meeves SG, Appajosyula S: Efficacy and safety profile of fexofenadine HCL: A unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol 2003, 112:S69-S77.
  4. Rita Breier A, Nudelman NS, Steppe M, Schapoval EES: Isolation and structure elucidation of photodegradation products of fexofenadine. J Pharm Biomed Anal 2008, 46:250-257.
  5. Estelle F, Simons R: Antihistamines. In Allergy.. 2 edition. Edited by: Kaplan AP. Saunders WB Company, Philadelphia; 2002:834-863.
  6. Howarth PH: The choice of an H1-antihistamine for the 21st century. Clin Exp Allergy 2002, 2:18-25.
  7. https://www.drugs.com/mtm/fexofenadine. html
  8. Guo D, Zou J, Zhu Y, Lou S, Fan H, Qin Q: Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: application to a clinical pharmacokinetic study. Biomed Chromatogr 2010, 24:335-341.

Details

Primary Language

English

Subjects

Engineering

Journal Section

Research Article

Publication Date

December 31, 2021

Submission Date

December 25, 2021

Acceptance Date

January 3, 2022

Published in Issue

Year 2021 Number: 32

APA
Akbel, E., & Bulduk, İ. (2021). RP-HPLC Method Development and Validation for Quantification of Fexofenadine in Pharmaceutical Products. Avrupa Bilim Ve Teknoloji Dergisi, 32, 1048-1053. https://doi.org/10.31590/ejosat.1044758
AMA
1.Akbel E, Bulduk İ. RP-HPLC Method Development and Validation for Quantification of Fexofenadine in Pharmaceutical Products. EJOSAT. 2021;(32):1048-1053. doi:10.31590/ejosat.1044758
Chicago
Akbel, Erten, and İbrahim Bulduk. 2021. “RP-HPLC Method Development and Validation for Quantification of Fexofenadine in Pharmaceutical Products”. Avrupa Bilim Ve Teknoloji Dergisi, nos. 32: 1048-53. https://doi.org/10.31590/ejosat.1044758.
EndNote
Akbel E, Bulduk İ (December 1, 2021) RP-HPLC Method Development and Validation for Quantification of Fexofenadine in Pharmaceutical Products. Avrupa Bilim ve Teknoloji Dergisi 32 1048–1053.
IEEE
[1]E. Akbel and İ. Bulduk, “RP-HPLC Method Development and Validation for Quantification of Fexofenadine in Pharmaceutical Products”, EJOSAT, no. 32, pp. 1048–1053, Dec. 2021, doi: 10.31590/ejosat.1044758.
ISNAD
Akbel, Erten - Bulduk, İbrahim. “RP-HPLC Method Development and Validation for Quantification of Fexofenadine in Pharmaceutical Products”. Avrupa Bilim ve Teknoloji Dergisi. 32 (December 1, 2021): 1048-1053. https://doi.org/10.31590/ejosat.1044758.
JAMA
1.Akbel E, Bulduk İ. RP-HPLC Method Development and Validation for Quantification of Fexofenadine in Pharmaceutical Products. EJOSAT. 2021;:1048–1053.
MLA
Akbel, Erten, and İbrahim Bulduk. “RP-HPLC Method Development and Validation for Quantification of Fexofenadine in Pharmaceutical Products”. Avrupa Bilim Ve Teknoloji Dergisi, no. 32, Dec. 2021, pp. 1048-53, doi:10.31590/ejosat.1044758.
Vancouver
1.Erten Akbel, İbrahim Bulduk. RP-HPLC Method Development and Validation for Quantification of Fexofenadine in Pharmaceutical Products. EJOSAT. 2021 Dec. 1;(32):1048-53. doi:10.31590/ejosat.1044758

Cited By